Yarrow Bioscience, Inc. (YARW) company profile
Close on Nov 17, 2026Market cap $37.94MP/E –Yield –
About Yarrow Bioscience
Pharmaceutical Preparations, SIC 2834
VYNE is a clinical-stage biopharmaceutical company that develops therapies for inflammatory and immune-mediated conditions with high unmet medical needs. The company focuses on small molecule bromodomain and extra-terminal domain BET inhibitors, specifically through its InhiBET platform. Its pipeline includes VYN202, an oral BD2-selective inhibitor under evaluation for various autoimmune and inflammatory disorders, and repibresib, a topical pan-bromodomain inhibitor. Because its drug candidates remain in clinical development, the company does not yet sell commercial products to end consumers, but its research targets patients afflicted with serious inflammatory conditions.
The company maintains no internal manufacturing facilities and relies entirely on third-party contract organizations to produce materials for preclinical and clinical testing. It holds exclusive global rights to its core BET inhibitor compounds, and its intellectual property encompasses granted patents and pending applications across numerous international jurisdictions, including the United States, Europe, the United Kingdom, Japan, and China. The provided text does not identify the location of the company's corporate headquarters or total employee headcount.
Summary of the business section of Yarrow Bioscience's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Yarrow Bioscience, Inc.
- Headquarters
- New Haven, CT
- Address
- 470 James Street, Suite 007 06513
- Phone
- (203) 433-7577
- Employees
- 10, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Baker Tilly US, LLP, Tewksbury, Massachusetts
Stock & identifiers
- Ticker
- YARW
- Former tickers
- VYNE until Jul 28, 2026; MNLO until Sep 8, 2020
- Exchange
- Nasdaq
- IPO date
- Jan 26, 2018
- Shares outstanding
- 3M, Aug 10, 2026
- Public float
- $32.00M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-50 reverse, Jul 27, 2026; 1-for-18 reverse, Feb 13, 2023; 1-for-4 reverse, Feb 16, 2021
- SEC CIK
- 1566044
- CUSIP
- 92941V407
- ISIN
- US92941V4077
- FIGI
- BBG00H5W8GM8
- Share class FIGI
- BBG00H5W8GN7
- EIN
- 45-3757789
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Rebecca Frey | Chief Executive Officer, Director | – |
| David Domzalski | PRESIDENT AND CEO, Director | 347,174 |
| Tyler Zeronda | Chief Financial Officer | 74,918 |
| Rachael Alford | Chief Operating Officer | – |
| Steven Ryder | Chief Medical Officer | – |
| Lori Payton | Chief Development Officer | – |
| Mutya Harsch | CHIEF LEGAL OFFICER AND GC | 95,918 |
| Iain Stuart | CHIEF SCIENTIFIC OFFICER | 95,944 |
| Capital GP X. LLC OrbiMed | Director | – |
| Genesis GP LLC OrbiMed | Director | – |
| Steven L. Hoerter | Director | – |
| Advisors Llc Orbimed | Director | 233,019 |
| Mona Ashiya | Director | 33,287 |
| Peter B. Silverman | Director | – |
| William Richard White | Director | – |
| Sven Ante Lundberg | Director | – |
| Elisabeth Sandoval Little | Director | – |
| Steven L. Basta | Director | 853,942 |
| Patrick G. Lepore | Director | 51,472 |
| Sharon Barbari | Director | 75,000 |
| Christine Borowski | Director | – |
| Anthony D. Bruno | Director | 120,123 |
Executive compensation, fiscal 2024
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| David Domzalski President and Chief Executive Officer | $637.56K | $524.25K | $436.50K | $361.50K | $13.80K | $1.97M | -27% |
| Iain Stuart Chief Scientific Officer | $455.56K | $145.63K | $121.25K | $172.20K | $13.80K | $908.43K | -22% |
| Mutya Harsch Chief Legal Officer, General Counsel and Secretary | $443.28K | $145.63K | $121.25K | $167.56K | $13.80K | $891.52K | -21% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Jan 26, 2018
- Offer price
- $17.00
- Securities offered
- 7,000,000
- Gross proceeds
- $119.00M
- Exchange
- Nasdaq
- First trading day
- Jan 25, 2018
- First-day close
- $28.71+68.9%
- Lock-up ends (est.)
- Jul 24, 2018
“The initial public offering price is $17.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had a total of 10 full-time employees.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?